DR-214 Genomic landscape of tumor sensitivity and resistance to anti-cancer drugs in colorectal cancer patients
Colorectal cancer (CRC) ranks as the second most lethal cancer and the third most prevalent malignant tumor worldwide. Despite of continuous development of a new targeted therapies and well defined molecular targets of potential sensitivity, the mechanisms associated with resistance events are poorly understood. Therefore, we will perform whole-genome sequencing data analyses on CRC patients genomes downloaded from Hartwig Medical Foundation and will identify a set of individual genomic features, underlying tumor drug sensitivity and/or resistance. Obtained data will be used to develop a clinical predictor that will help patient stratification toward anti-cancer therapies, improving long-term clinical outcomes.
Pawel Zawadzki, Adam Mickiewicz University in Poznań, Poland
Back to newsMore news
Arno de Quaasteniet new member of the board of Hartwig Medical Foundation
Hartwig Medical Foundation is pleased to announce that as of October 1, 2024, Arno de Quaasteniet (1977) has been appointed …
SAGE: New algorithm for analysis of tumor DNA reveals mutations previously not found
At Hartwig we “analyse sequenced tumor DNA”. This is something we try to continuously improve. These analyses are shared with …
Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients
Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.